The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.

For a non-hematologist like me, what was striking at the very outset while beginning to learn about cell counting, was the remarkable way in which techniques of cell counting (hematology) and particle counting (physics) have complemented and contributed to each other. It is indeed interesting…